anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides new benzofuranyl-tetrahydropyridines and -piperidines of the general formula I < IMAGE > (I) in which R1 and R2 independently of one another are hydrogen or lower alkyl or together are lower alkylene, R3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclo-lower alkyl or cyclo-lower alkyl-lower alkyl and Y1 and Y2 are each hydrogen or together are an additional bond, and the ring A is not further substituted or is further substituted by lower alkyl, lower alkoxy, halogen with an atomic number not more than 35, cyano or hydroxyl and the pharmaceutically acceptable acid addition salts thereof, and antidepressant preparations containing these compounds. The compounds according to the invention have valuable pharmacological properties. In particular, they inhibit the absorption of serotonin by mesencephalic synaptosomes, the serotonin depletion induced in the brain of rats by H 75/12, the absorption of noradrenalin by mesencephalic synaptosomes in rats and the noradrenalin depletion induced in the brain of rats by H 77/77. In the same dosage they also effect inhibition of monoamino-oxidase in the brain of rats and in the liver of rats. Furthermore, they intensify the "head twitch" induced by 5-hydroxy-tryptophan, and are distinguished by good tolerance. The compounds of the general formula I and their pharmaceutically acceptable acid addition salts can therefore be used as psychopharmaceuticals and in particular as antidepressants.
PURPOSE:To fit a patch to an application site, by uniformly coating a substrate with a drug, further sticking a release liner to the drug layer and then punching the substrate and the drug, while selecting any shape, size and thickness depending upon action and use purpose of the drug. CONSTITUTION:A drug 22 is spread and applied to a beltlike substrate 21, a release liner 25 is laminated to the surface of the drug 22 layer to give a beltlike patch 33. Then the patch is inverted, the substrate 21 and the drug 22 are punched at given intervals by a roll type punching machine 29, while leaving the release liner 25 to separate patches 23 from excessive outer peripheral parts. Further the excessive parts are removed from the release liner 25. Consequently, the patches 23 are placed at uniform intervals on the release liner 25. By this method, shape, size, thickness, etc., of the drug can be arbitrarily determined and the shape of a tacky sheet can also be fixed arbitrarily. Since the release liner is in a connected state, the patches can be advantageously produced by a series of mechanical assembly-line operation.
Diabetes mellitus is the most common cause of neuropathy in the Western World, with up to 50% of patients developing neuropathy as a long-term complication of the illness, of whom 10% experience pain. Diabetic neuropathy most often affects the lower extremities and may be severe if inadequately treated. Blood glucose control is a critical treatment element, and several medications have been demonstrated to be effective in treating Diabetic Peripheral Neuropathy (DPN), including antiepileptic drugs, antidepressants and opioid analgesics. These medications are often limited by incomplete pain relief and side effects. This is a randomized (study medication is assigned by chance), double-blind (neither the Investigator or the patient know the name of the assigned study medication), placebo-controlled, crossover, parallel-group, multicenter study to determine the effectiveness and safety of 200 mg of RWJ-333369 given twice daily by mouth for 4 weeks compared with placebo in patients with DPN. The study hypothesis is that 200 mg of RWJ-333369 given twice daily by mouth for 4 weeks will be more effective than placebo in reducing pain due to DPN, as measured by average daily DPN pain scores. Patients will receive 200 mg of RWJ-333369 or matching placebo tablets, given in equally divided doses twice daily by mouth with or without food, for 4 weeks in each of the 2 treatment periods.
This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 5 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be \<15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (\<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.
Chronic rhinosinusitis (CRS) is a significant public health problem. Bacterial colonization and impaired mucociliary clearance play a significant role in the inflammatory process. Several inflammatory pathways and host defense elements are altered in CRS, which may contribute to observed differences in the microbiome. To date, researching CRS has been difficult due to limited access to the studied tissue and a lack of available biomarkers. Ongoing scientific research is increasingly based on simple and objective analytical methods, including sensors, detection with PCR, and sequencing. Future research on microbiota and human factors should also include genomics, transcriptomics, and metabolomics approaches. This report analyzes the changes that occur in the paranasal sinuses of people with acute and chronic rhinosinusitis, the composition of the microbiota, the human genetic markers that may shed light on the predisposition to CRS, and the advantages and disadvantages of classical and molecular diagnostic methods, as well as addressing the difficulties of sinusitis treatment.
Articles for increasing lubrication of a joint are described herein. The articles include resorbable, biocompatible particles having a glass transition temperature within a joint of less than about 37° C. and capable of increasing fluid movement within the joint compared to synovial fluid, viscosupplemental fluid, or combinations thereof. A composition for increasing lubrication of a joint is also disclosed. The composition includes the resorbable, biocompatible particles and a carrier fluid. Methods of lubricating a joint and treating disease affecting the joint such as osteoarthritis are also described herein. The methods include introducing the resorbable, biocompatible particles into a joint.
Migrant patients share the same diseases as natives, but biological or environmental differences may lead to distinct prevalence and manifestations of certain syndromes. Some common conditions in Primary Care stand out, such as fever, diarrhea, anemia, eosinophilia, and chronic cough, where it is important to have a special consideration. Fever may indicate a serious imported illness, and malaria should always be ruled out. Diarrhea is generally of infectious origin, and in most cases, management is outpatient. Anemia may indicate malnutrition or malabsorption, while eosinophilia may indicate a parasitic infection. Lastly, chronic cough may be a sign of tuberculosis, especially in immigrants from endemic areas. Family medicine holds a privileged position for the comprehensive, culturally sensitive, and person-centered approach to these conditions.
FIELD: medicine. SUBSTANCE: new compound having six-member cycle is camptotecin derivative of general formula I. The compound is prepared from aminoketone and pyranoindolysine compound by reaction of i.e. closing of the ring. The compound is readily soluble and has excellent antitumor activity and high degree of safety, it can be used as antitumor agent for treatment tumors of various types. Compound of formula I: $$$. EFFECT: improved properties of the hexacyclic compound. 9 cl, 50 ex, 1 tbl
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes the novel derivatives of 1,1-bis(heteroazolyl)alkanes of the general formula:   where X 1  and X 2  mean independently O, S; Y 1  and Y 2  mean independently C or N under condition that at least one of Y 1  and Y 2  is N; Y 3  and Y 4  mean independently C or N under condition that at least one of Y 3  and Y 4  is N; each of R 1  and R 2  means one or two groups taken independently of H, lower alkyl, lower (alkoxy-lower)-alkyl and A means   where W is O, NH; R 3  means H, alkyl or lower acyl; R 4  means lower alkyl or lower perfluoroalkyl, or their optical isomers and racemates. Invention relates to also their pharmaceutically acceptable salts with acids under condition that 1,1-di-(2-thiazolyl)-ethanol is excluded. The above indicated compounds are able to inhibit the slow neurons dying off in bilateral occlusion ischemia model in gerbils. Compounds show valuable properties in treatment of patients with acute and chronic neuropsychiatric disorders. Invention describes also method of their synthesis, pharmaceutical composition and method of treatment using compounds of the formula (I). EFFECT: new compounds indicated above, valuable medicinal properties. 9 cl
BACKGROUND AND AIMS: Smoking is recognised as an independent risk factor in the development of chronic pancreatitis (CP). Cystic fibrosis transmembrane conductance regulator (CFTR) function and ductal fluid and bicarbonate secretion are also known to be impaired in CP, so it is crucial to understand the relationships between smoking, pancreatic ductal function and the development of CP.
METHODS: We measured sweat chloride (Cl-) concentrations in patients with and without CP, both smokers and non-smokers, to assess CFTR activity. Serum heavy metal levels and tissue cadmium concentrations were determined by mass spectrometry in smoking and non-smoking patients. Guinea pigs were exposed to cigarette smoke, and cigarette smoke extract (CSE) was prepared to characterise its effects on pancreatic HCO3 - and fluid secretion and CFTR function. We administered cerulein to both the smoking and non-smoking groups of mice to induce pancreatitis.
RESULTS: Sweat samples from smokers, both with and without CP, exhibited elevated Cl- concentrations compared to those from non-smokers, indicating a decrease in CFTR activity due to smoking. Pancreatic tissues from smokers, regardless of CP status, displayed lower CFTR expression than those from non-smokers. Serum levels of cadmium and mercury, as well as pancreatic tissue cadmium, were increased in smokers. Smoking, CSE, cadmium, mercury and nicotine all hindered fluid and HCO3 - secretion and CFTR activity in pancreatic ductal cells. These effects were mediated by sustained increases in intracellular calcium ([Ca2+]i), depletion of intracellular ATP (ATPi) and mitochondrial membrane depolarisation.
CONCLUSION: Smoking impairs pancreatic ductal function and contributes to the development of CP. Heavy metals, notably cadmium, play a significant role in the harmful effects of smoking.
KEY POINTS: Smoking and cigarette smoke extract diminish pancreatic ductal fluid and HCO3 - secretion as well as the expression and function of CFTR Cd and Hg concentrations are significantly higher in the serum samples of smokers Cd accumulates in the pancreatic tissue of smokers.
Pharmacy furniture provided with control of the return of medication orders by means of a visual and acoustic signal, designed to store medications and pharmaceutical products that have been ordered by patients until they pick them up, so that, if not, they can be returned by the patient. pharmaceutical in a maximum of days available, characterized by containing the following elements: A. A shelf-type furniture divided into compartments (1) designed for the placement of a set of medications grouped by date of entry, plus an additional area with a closing device (3) for the storage of narcotics. B. Status change button (4) for each medication compartment, which includes RGB LED light in alternative colors of red to indicate the need for action and green to identify the available compartment corresponding to that day. C. A buzzer to generate an audible alarm, of defined duration and intervals and to be activated coinciding with the light of a compartment that turns red, as an indication that the return of the medications must be carried out immediately containing. D. Control circuit connected to the electrical network based on a very low voltage direct current adapter device, a microcontroller and a set of relays. E. Metal space (5) per compartment (1) where you can indicate products that cannot be in the corresponding space. F. Magnet volume product reminder (6). G. Product reminder magnet on the refrigerator (7). H. Narcotic product reminder magnet (8).  (Machine-translation by Google Translate, not legally binding)
ctDNA is obtained from plasma rather than serum, as the latter contains more DNA released from immune cells during clotting. Blood should be drawn into a K2EDTA or cell stabilization tube (e.g., Streck cfDNA collection tube). Plasma isolation should be performed as soon as possible, no later than 24 hours, using K2EDTA (preferably within 4-6 hours) and, if using cell stabilization tubes, within 2-7 days, temporarily stored at 4°C.

Sample disposal procedure: collect whole anticoagulated blood, gently invert to fully anticoagulate, plasma fractionation should be performed as soon as possible, no later than 24 hours, temporarily stored at 4°C using K2EDTA (preferably within 4-6 hours), and stored at -80°C for long term. The collected anticoagulant blood is placed in an ice box containing ice packs and transported vertically to a centrifugable laboratory. Centrifuge at 3000 rpm at 4°C for 15 min, take the upper layer, and aliquot 0.5 mL/tube into 1.5 mL centrifuge tubes. Cryopreserved at -80 °C, 1 mL of whole blood yields approximately 0.5 mL of plasma.
Detailed Description: The investigators are registering all end stage renal disease (ESRD) patients receiving peritoneal dialysis (PD) treatment, and developing a PD database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education, etc), clinical characteristics (primary cause of ESRD, dialysis prescription, patient's condition and lab measurements of serum, urine, and dialysate), drug information, complications and scores of quality of life at the baseline will be collected. Patients will be followed up every 3 months. Demographic and clinical characteristics, complications, drug information of patients will be collected at each visit. The patients' clinical outcomes, such as mortality (including all-cause mortality and cardiovascular disease mortality), technical survival, kidney transplantation, transfer to hemodialysis, hospitalization, occurrence of peritonitis, etc. were also followed up till the end of the study. The data of patient survival, technical survival, peritonitis rate, hospitalization rate, clinical lab parameters, longitudinal changes of residual renal function and peritoneum function, peritonitis rate, hospitalization rate, clinical lab parameters and quality of life for PD patients will be analyzed using the PD database.
The aim of the EPIC trial is to assess if a multicomponent computer-based system incorporated into the workflow can reduce days of therapy (DOT) per admission after cardiovascular surgeries in the intervention surgical teams compared with controlled surgical teams, over a one-year period. This trial is an open-label, two-arm, cluster-randomized, controlled trial with cardiovascular surgical teams as the unit of randomization. Eligible teams with written consent are randomized to the intervention or control arm by random number generator. Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm. Teams in the control arm will continue with usual clinical care. The intervention includes re-evaluation alerts and decision support for the duration of antimicrobial treatment, re-evaluation alerts and decision support for the choice of antimicrobial, and quality control audit and feedback. Nine teams per arm with an average size of 1125 admissions will be recruited. Primary outcome will be the overall systemic antibiotic use measured in DOT of systemic antibiotic use per admission. Secondary outcomes include a series of indices to evaluate antimicrobial use, microbial resistance, perioperative infection outcomes, patient safety, resource consumption and user compliance/satisfaction.
In clinical trials the use of levobunolol hydrochloride has been associated with transient ocular burning and stinging in up to 1 in 3 patients, and with blepharoconjunctivitis in up to 1 in 20 patients. Decreases in heart rate and blood pressure have been reported (see CONTRAINDICATIONS and WARNINGS).

The following adverse effects have been reported rarely with the use of levobunolol: iridocyclitis, headache, transient ataxia, dizziness, lethargy, urticaria and pruritus.

Decreased corneal sensitivity has been noted in a small number of patients. Although levobunolol has minimal membrane-stabilizing activity, there remains a possibility of decreased corneal sensitivity after prolonged use.

The following additional adverse reactions have been reported either with levobunolol or ophthalmic use of other beta-adrenergic receptor blocking agents: BODY AS A WHOLE: Headache, asthenia, chest pain. CARDIOVASCULAR: Bradycardia, arrhythmia, hypotension, syncope, heart block, cerebral vascular accident, cerebral ischemia, congestive heart failure, palpitation, cardiac arrest. DIGESTIVE: Nausea, diarrhea. PSYCHIATRIC: Depression, confusion, increase in signs and symptoms of myasthenia gravis, paresthesia. SKIN: Hypersensitivity, including localized and generalized rash, alopecia, Stevens-Johnson Syndrome. RESPIRATORY: Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, dyspnea, nasal congestion. UROGENITAL: Impotence. ENDOCRINE: Masked symptoms of hypoglycemia in insulin-dependent diabetics (see WARNINGS). SPECIAL SENSES: Signs and symptoms of keratitis, blepharoptosis, visual disturbances including refractive changes (due to withdrawal of miotic therapy in some cases), diplopia, ptosis.

Other reactions associated with the oral use of non-selective adrenergic receptor blocking agents should be considered potential effects with ophthalmic use of these agents.
PURPOSE:To obtain an ultraviolet absorber which is highly safe, has an excellent ultraviolet absorbing effect and is desirable as e.g. a starting material for an external dermatologic preparation by using a specified diphenyl unsaturated compound which is a natural analogue. CONSTITUTION:This absorber is produced by using a diphenyl unsaturated compound represented by formula I (wherein R1, R2 and R3 are each H, OH or alkoxyl; provided at least one of them is OH or alkoxyl). A compound of formula I (wherein R1 is OH, and R2 and R3 are each H) is produced by reacting o-hydroxyacetophenone with cinnamaldehyde. The absorber can also be produced by using a compound represented by formula II (wherein R is H or OH), formula III (wherein R1, R2, R3 and R4 are each H or alkoxyl) or formula IV. An external dermatologic preparation obtained by mixing the obtained ultraviolet absorber with necessary additives such as a surfactant and a humectant is safe and has a high ultraviolet absorbing effect.
Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
Ultra-low crosslinked microgels made of an ultra-low crosslinked polymer are provided. The microgels, also referred to as Platelet-like Particles (PLPs), preferably have <0.5% crosslinking densities. One or more of the polymers are conjugated with a fibrin-binding element or moiety, preferably H6, in an amount effective to confer to the microgel selective binding to fibrin under physiological conditions. The PLPs can recapitulate multiple key functions of platelets including binding, stabilizing and enhancing fibrin clot formation, responsiveness to injury cues, and induction of clot contraction. In a preferred embodiment, the microgel or PLP has little or no binding to soluble fibrinogen under physiological conditions compared to its binding to fibrin. The microgels or PLPs are prepared using crosslinker-free synthesis conditions, and can promote or induce clotting and clot contraction.
<P>PROBLEM TO BE SOLVED: To develop a new active ingredient for inhibiting a matrix metalloproteinase (MMP), and to develop a supply source for the same.  <P>SOLUTION: A matrix metalloproteinase (MMP) inhibitor contains artepillin C which is a compound expressed by structural formula (I). In a preferable embodiment, the artepillin C for composing the MMP inhibitor is derived from Baccharis dracunculifolia. In another preferable embodiment, the artepillin C is derived from propolis, especially, the propolis produced in Brazil. The MMP inhibitor is utilized as a composition for food and drink use, or for oral use, which contains the inhibitor.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
The invention discloses a combined moxibustion drug for promoting blood circulation, removing blood stasis, soothing liver and strengthening spleen. The combined moxibustion drug is characterized by being prepared by the following raw materials: rheum officinale, felwort, the root of red-rooted salvia, radix curcumae, turmeric, radix rehmanniae, the root of kudzu vine, radix polygonati officinalis, hawthorn, borneol, green tea, pericarpium citri reticulatae viride and fructus aurantii. A preparation method provided by the invention comprises the following steps: applying the raw materials except the borneol and crushing the raw materials into fine powder; singly porphyrizing the borneol, equivalently adding the borneol into the fine powder and filtering through a 100-mesh sieve; and uniformly mixing, thereby obtaining the combined moxibustion drug. During a use process, 5g fine powder is taken, 5ml mature vinegar is added and a paste is prepared, so that a drug cake with the thickness about 0.2-0.3cm and the diameter about 2-3cm is prepared for standby. The combined moxibustion drug has the functions of promoting blood circulation, removing blood stasis, dredging channel, soothing liver, regulating vital energy, dispelling melancholy, strengthening spleen, eliminating dampness and eliminating phlegm. The combined moxibustion drug has the main function of treating the fatty liver caused by liver dysfunction, liver blood stasis, dysfunction of the spleen in transport, un-melted dampness pathogen, endogenous damp formation, and the like.